HCM Fundamental Analysis - HUTCHMED CHINA-ADR

Fundamental Rating

HCM gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. HCM has an average financial health and profitability rating. HCM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!

Quickly go to:

1. Profitability

1.1 Basic Checks

HCM had positive earnings in the past year.

HCM had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: HCM reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: HCM reported negative operating cash flow in multiple years.

1.2 Ratios

HCM's Return On Assets of 26.29% is amongst the best of the industry. HCM outperforms 97.93% of its industry peers.

The Return On Equity of HCM (37.99%) is better than 96.37% of its industry peers.

		Industry Rank	Sector Rank
ROA	26.29%
ROE	37.99%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 77.53%, HCM belongs to the top of the industry, outperforming 98.96% of the companies in the same industry.

HCM's Gross Margin of 44.15% is fine compared to the rest of the industry. HCM outperforms 61.66% of its industry peers.

In the last couple of years the Gross Margin of HCM has grown nicely.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	77.53%
GM	44.15%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y17.54%

GM growth 5Y15.38%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.

HCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 3.84 indicates that HCM is not in any danger for bankruptcy at the moment.

HCM has a better Altman-Z score (3.84) than 75.13% of its industry peers.

A Debt/Equity ratio of 0.08 indicates that HCM is not too dependend on debt financing.

HCM's Debt to Equity ratio of 0.08 is in line compared to the rest of the industry. HCM outperforms 52.33% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	3.84

ROIC/WACCN/A

WACC9.99%

2.3 Liquidity

HCM has a Current Ratio of 4.65. This indicates that HCM is financially healthy and has no problem in meeting its short term obligations.

HCM has a Current ratio of 4.65. This is in the better half of the industry: HCM outperforms 68.39% of its industry peers.

HCM has a Quick Ratio of 4.51. This indicates that HCM is financially healthy and has no problem in meeting its short term obligations.

HCM's Quick ratio of 4.51 is fine compared to the rest of the industry. HCM outperforms 69.43% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.65
Quick Ratio	4.51

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1172.34%, which is quite impressive.

HCM shows a decrease in Revenue. In the last year, the revenue decreased by -1.41%.

HCM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.20% yearly.

EPS 1Y (TTM)1172.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1661.49%

Revenue 1Y (TTM)-1.41%

Revenue growth 3Y20.96%

Revenue growth 5Y25.2%

Sales Q2Q%-9.16%

3.2 Future

Based on estimates for the next years, HCM will show a very strong growth in Earnings Per Share. The EPS will grow by 52.63% on average per year.

Based on estimates for the next years, HCM will show a very strong growth in Revenue. The Revenue will grow by 20.25% on average per year.

EPS Next Y863.46%

EPS Next 2Y87.5%

EPS Next 3Y63.37%

EPS Next 5Y52.63%

Revenue Next Year-6.68%

Revenue Next 2Y4.64%

Revenue Next 3Y8.85%

Revenue Next 5Y20.25%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 5.73 indicates a rather cheap valuation of HCM.

Based on the Price/Earnings ratio, HCM is valued cheaply inside the industry as 95.85% of the companies are valued more expensively.

HCM's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.08.

With a Price/Forward Earnings ratio of 31.71, HCM can be considered very expensive at the moment.

70.47% of the companies in the same industry are more expensive than HCM, based on the Price/Forward Earnings ratio.

HCM's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.67.

		Industry Rank	Sector Rank
PE	5.73
Fwd PE	31.71

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

HCM's earnings are expected to grow with 63.37% in the coming years. This may justify a more expensive valuation.

PEG (NY)0.01

PEG (5Y)N/A

EPS Next 2Y87.5%

EPS Next 3Y63.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for HCM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HUTCHMED CHINA-ADR

NASDAQ:HCM (8/26/2025, 8:00:01 PM)

15.63

-0.3 (-1.88%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/bmo

Earnings (Next)N/A N/A

Inst Owners21.98%

Inst Owner Change-6.75%

Ins Owners0.58%

Ins Owner ChangeN/A

Market Cap2.67B

Analysts85.19

Price Target17.41 (11.39%)

Short Float %0.4%

Short Ratio6.1

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-3.77%

PT rev (3m)1.42%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)4.52%

EPS NY rev (3m)4.43%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-10.56%

Revenue NY rev (3m)-10.56%

Valuation

		Industry Rank	Sector Rank
PE	5.73
Fwd PE	31.71
P/S	4.44
P/FCF	N/A
P/OCF	N/A
P/B	2.18
P/tB	2.18
EV/EBITDA	N/A

EPS(TTM)2.73

EY17.47%

EPS(NY)0.49

Fwd EY3.15%

FCF(TTM)-0.35

FCFYN/A

OCF(TTM)-0.19

OCFYN/A

SpS3.52

BVpS7.18

TBVpS7.18

PEG (NY)0.01

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	26.29%
ROE	37.99%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	77.53%
GM	44.15%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y17.54%

GM growth 5Y15.38%

F-Score5

Asset Turnover0.34

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	221.94%
Cap/Sales	4.5%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.65
Quick Ratio	4.51
Altman-Z	3.84

F-Score5

WACC9.99%

ROIC/WACCN/A

Cap/Depr(3y)321.95%

Cap/Depr(5y)304.39%

Cap/Sales(3y)5.11%

Cap/Sales(5y)5.73%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)1172.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1661.49%

EPS Next Y863.46%

EPS Next 2Y87.5%

EPS Next 3Y63.37%

EPS Next 5Y52.63%

Revenue 1Y (TTM)-1.41%

Revenue growth 3Y20.96%

Revenue growth 5Y25.2%

Sales Q2Q%-9.16%

Revenue Next Year-6.68%

Revenue Next 2Y4.64%

Revenue Next 3Y8.85%

Revenue Next 5Y20.25%

EBIT growth 1Y83.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year123.05%

EBIT Next 3Y61.78%

EBIT Next 5Y47.13%

FCF growth 1Y-2591.94%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-168.32%

OCF growth 3YN/A

OCF growth 5YN/A

HUTCHMED CHINA-ADR (HCM) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens